Tag: Merck KGaA
Merck KGaA and Mersana Therapeutics Sign Research Collaboration and Commercial License...
German based Merck KGaA, and Mersana Therapeutics USA have signed a research collaboration and commercial license agreement to discover novel antibody-drug conjugates (ADCs) leveraging...
Sutro Biopharma Receives Milestone Payment for Bispecific Antibody-Drug Conjugate from Merck
South San Francisco-based clinical-stage biotechnology company Sutro Biopharma has received a milestone payment under its collaboration and license agreement with the healthcare division of...
Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific...
Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, in the United...
Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development
Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development of NBE-002, the company's first...
California Life Sciences Association Rewards Sutro Biopharma with Outstanding Partner Award
This week, during the California Life Sciences Association (CLSA) annual Pantheon Ceremony (DiNA Awards), Sutro Biopharma received the Outstanding Partner Award. By giving this award to Sutro, the...
